PEPTIDE RESEARCH TOPIC

Tirzepatide (Tirz) Research Peptide

Browse Tirzepatide research information, terminology, comparisons, quality documentation, and frequently searched questions.

TOPIC OVERVIEW

About Tirzepatide

Identity and names

Tirzepatide is the formal active-compound name; Tirz and Tirz peptide are informal abbreviations.

  • Mounjaro and Zepbound identify specific finished products rather than every material described as tirzepatide.

Compound type

Tirzepatide is a synthetic, acylated peptide with agonist activity at both GIP and GLP-1 receptors.

  • Its fatty-diacid component supports albumin binding and prolonged exposure.

Mechanism

The compound activates the receptors used by the incretin hormones GIP and GLP-1.

  • Both pathways participate in glucose-dependent insulin signaling; GLP-1 activity also contributes to glucagon regulation, appetite-related signaling, and gastric-emptying effects.

Research focus and evidence

Evidence includes receptor studies, preclinical work, controlled human trials, and post-authorization information for named prescription products.

  • Research questions include dual-receptor pharmacology, metabolic endpoints, formulation, stability, analytical testing, and comparison with semaglutide or retatrutide.
  • Human outcome data apply to studied populations and cannot establish the properties of an unverified vial.

Regulatory status and limits

Authorization applies to specific products, indications, and manufacturing standards rather than every item advertised as tirzepatide.

  • Regulated, compounded, and research-labeled materials may differ in formulation, concentration, excipients, sterility, quality controls, and supporting clinical evidence.
Topics covered
  • dual-receptor terminology
  • GIP and GLP-1 pathways
  • storage and handling
  • purity and identity testing
  • comparative research topics
Common names and related terms: tirzepatide, tirz, tirz peptide
RESEARCH TRACKER

Tirzepatide Development & Clinical Research

Current programs, research areas, study status, enrollment, and expected completion dates organized from primary registry records.

LAST VERIFIEDSeptember 30, 2026
Registered records295
Active studies195
Completed studies91
FDA-listed brands2
DeveloperEli Lilly and Company
AliasesLY3298176, Mounjaro, Zepbound
Biological targetsGIP receptor, GLP-1 receptor
Development stageApproved medicine with ongoing Phase 4 research
Regulatory statusFDA-approved formulations exist

What current projects are studying

ObesityAtrial FibrillationObesity & OverweightCatheter AblationHeart Failure With Preserved Ejection Fraction (HFpEF)TirzepatideDiabetes Mellitus, Type 2Overweight
SELECTED CURRENT RESEARCH

Latest and important projects

Showing 5 of 195 active studies
REGISTERED STUDYNCT07247084

A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

Obesity

Phase
Phase 4
Status
Recruiting
Enrollment
3,000 Estimated
Expected completion
Jul 2032
Record updated
Sep 9, 2026
Lead sponsor
Eli Lilly and Company
TEAR-AFNCT07715929

Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients

Atrial Fibrillation · Obesity & Overweight · Catheter Ablation

Phase
Phase 4
Status
Not yet recruiting
Enrollment
710 Estimated
Expected completion
Dec 30, 2029
Record updated
Jul 21, 2026
Lead sponsor
Yunlong Wang
TEAR-AF-HFpEFNCT07630454

Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF

Atrial Fibrillation · Heart Failure With Preserved Ejection Fraction (HFpEF) · Tirzepatide

Phase
Phase 4
Status
Not yet recruiting
Enrollment
602 Estimated
Expected completion
Dec 1, 2029
Record updated
Jun 5, 2026
Lead sponsor
Yunlong Wang
REGISTERED STUDYNCT07438444

A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity

Diabetes Mellitus, Type 2 · Obesity · Overweight

Phase
Phase 4
Status
Active, not recruiting
Enrollment
344 Estimated
Expected completion
Jul 2027
Record updated
Aug 21, 2026
Lead sponsor
Eli Lilly and Company
REGISTERED STUDYNCT06864026

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

Psoriatic Arthritis · Overweight or Obesity

Phase
Phase 4
Status
Active, not recruiting
Enrollment
200 Estimated
Expected completion
Aug 2027
Record updated
Sep 21, 2026
Lead sponsor
Eli Lilly and Company
START HERE

Essential Tirzepatide guides

TIRZEPATIDE KNOWLEDGE ARTICLESPage 1 of 24
01
KNOWLEDGE ARTICLE

Hallandale Tirz: Compounded Tirzepatide Explained

Hallandale tirz explained: compare compounded tirzepatide with branded medicines, read concentration labels, and check current dispensing and regulatory status.

↗
03
KNOWLEDGE ARTICLE

Brello Tirzepatide: What It Is, Cost, and Safety

Brello tirzepatide is compounded GLP-1 medication sold through a telehealth platform. Learn how it works, how it compares to Zepbound, and key safety facts.

↗
05
KNOWLEDGE ARTICLE

Can Tirzepatide Cause Body Aches? What to Know

Can tirzepatide cause body aches? Learn how common muscle and joint soreness really is on Mounjaro or Zepbound, what triggers it, and when to call your doctor.

↗
06
KNOWLEDGE ARTICLE

Tirz Tetovo: What the Term Means and Buyer Risks

Tirz Tetovo combines tirzepatide shorthand with a North Macedonia shipping city. Learn what the term means, how the gray market works, and safer options.

↗
09
KNOWLEDGE ARTICLE

Ion Peptide Tirzepatide: What You Need to Know

Ion peptide tirzepatide is sold as a research chemical, not a prescription drug. Learn what it is, how it compares to FDA-approved tirzepatide, and safety.

↗
16
KNOWLEDGE ARTICLE

2.5 mg Tirzepatide: Starting Dose Explained

2.5 mg tirzepatide is the weekly starting dose of Mounjaro and Zepbound. Learn what it does, how long you stay on it, and when your dose increases.

↗
18
KNOWLEDGE ARTICLE

Compound Tirzepatide Reviews: What Users Report

Compound tirzepatide reviews reveal mixed user experiences, availability questions, and safety concerns. Learn what to check before choosing a provider.

↗